1. Sharma, R., Marwaha, R. K., Arya, A. K., Paharia, K., Saha, A., Gupta, P., Saini, H., & Sati, H. C. (2026). Establishment of normal serum androgen levels in healthy Indian adolescent school-going girls by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Endocrine, 91(1), 195. https://doi.org/10.1007/s12020-026-04668-7
2. Sahni, D., Kumar, B., Porwal, S., Arya, A. K., Akhtar, M. S., & Bharati, A. P. (2026). Investigating the role of FKBP4 in testis germ cell tumor via integrated in silico approach. In silico pharmacology, 14(1), 87. https://doi.org/10.1007/s40203-026-00592-w
3. Kumari, P., Bhadada, S. K., Arya, A. K., Kaur, J., Sachdeva, N., Saikia, U. N., Dahiya, D., Kumar, A., Kharbanda, C., & Rao, S. D. (2026). Aberrant Histone Methylation Profile in Patients with Sporadic Primary Hyperparathyroidism. The Journal of Clinical Endocrinology and Metabolism, 111(6), 1680–1691. https://doi.org/10.1210/clinem/dgaf668
4. Dhakal, P., Goyal, A., Jyotsna, V. P., Arya, A. K., Kandasamy, D., Agarwal, S., Tripathi, M., Kalaivani, M., Khadgawat, R., & Tandon, N. (2025). Clinical Profile and Treatment Outcomes of Tumour-Induced Osteomalacia - A Single-Centre Experience. Indian Journal of Endocrinology and Metabolism, 29(4), 414–422. https://doi.org/10.4103/ijem.ijem_43_25
5. Garg, R., Bhatt, M., Arya, A. K., Jyotsna, V. P., & Khadgawat, R. (2025). Two families, two pathways: a case series of 46, XY DSD with 17α-hydroxylase deficiency and isolated 17,20-lyase deficiency due to novel CYB5A variant. Journal of Pediatric Endocrinology & Metabolism, 38(6), 649–657. https://doi.org/10.1515/jpem-2024-0613
6. Kumari, P., Garg, S., Arya, A. K., Kaur, J., Sachdeva, N. K., Saikia, U. N., Dahiya, D., Bhadada, S. K., & Rao, S. D. (2025). Enhancer of zeste homolog 2 (EZH2) in endocrine tumors: current knowledge and future directions. Expert Opinion on Therapeutic Targets, 29(3), 159–169. https://doi.org/10.1080/14728222.2025.2482555
7. Arya, A. K., Kumari, P., Singh, P., & Bhadada, S. K. (2025). Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis. Best Practice & Research: Clinical Endocrinology & Metabolism, 39(2), 101985. https://doi.org/10.1016/j.beem.2025.101985
8. Mukherjee, S., Arya, A. K., Bhadada, S. K., Pal, R., Lohani, S., Gupta, A., & Rao, S. D. (2023). Characterization of primary hyperparathyroidism based on target organ involvement: An analysis from the Indian PHPT registry. Clinical Endocrinology, 99(2), 158–164. https://doi.org/10.1111/cen.14915
9. Kumari, P., Arya, A. K., Pal, R., Sood, A., Dahiya, D., Mukherjee, S., Rastogi, A., & Bhadada, S. K. (2022). Comparison of Profile of Primary Hyperparathyroidism With and Without Type 2 Diabetes Mellitus: Retrospective Analysis From the Indian Primary Hyperparathyroidism Registry. Endocrine Practice, 28(1), 96–101. https://doi.org/10.1016/j.eprac.2021.09.012
10. Singh, P., Bhadada, S. K., Arya, A. K., Saikia, U. N., Sachdeva, N., Dahiya, D., Kaur, J., Brandi, M. L., & Rao, S. D. (2022). Aberrant Epigenetic Alteration of PAX1 Expression Contributes to Parathyroid Tumorigenesis. The Journal of Clinical Endocrinology and Metabolism, 107(2), e783–e792. https://doi.org/10.1210/clinem/dgab626
11. Singh, P., Bhadada, S. K., Dahiya, D., Saikia, U. N., Arya, A. K., Sachdeva, N., Kaur, J., Behera, A., Brandi, M. L., & Rao, S. D. (2021). GCM2 Silencing in Parathyroid Adenoma Is Associated With Promoter Hypermethylation and Gain of Methylation on Histone 3. The Journal of Clinical Endocrinology and Metabolism, 106(10), e4084–e4096. https://doi.org/10.1210/clinem/dgab374
12. Arya, A. K., Bhadada, S. K., Kumari, P., Agrawal, K., Mukhopadhyay, S., Sarma, D., & Rao, S. D. (2021). Differences in Primary Hyperparathyroidism Between Pre- and Postmenopausal Women in India. Endocrine Practice, 27(7), 710–715. https://doi.org/10.1016/j.eprac.2020.12.012
13. Mukherjee, S., Arya, A. K., Bhadada, S. K., Saikia, U. N., Sood, A., Dahiya, D., & Behera, A. (2021). Parathyroid Carcinoma: An Experience from the Indian Primary Hyperparathyroidism Registry. Endocrine Practice, 27(9), 881–885. https://doi.org/10.1016/j.eprac.2021.01.014
14. Arya, A. K., Kumari, P., Bhadada, S. K., Agrawal, K., Singh, P., Mukherjee, S., Sood, A., & Rao, S. D. (2021). Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry. Journal of Bone and Mineral Metabolism, 39(2), 253–259. https://doi.org/10.1007/s00774-020-01142-w
15. Agrawal, K., Arya, A. K., Sood, A., Kumari, P., Singh, P., Sapara, M., Rastogi, A., Behera, A., & Bhadada, S. K. (2021). A detailed appraisal of renal manifestations in primary hyperparathyroidism from Indian PHPT registry: Before and after curative parathyroidectomy. Clinical Endocrinology, 94(3), 371–376. https://doi.org/10.1111/cen.14311
16. Singh, P., Bhadada, S. K., Dahiya, D., Arya, A. K., Saikia, U. N., Sachdeva, N., Kaur, J., Brandi, M. L., & Rao, S. D. (2020). Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas. The Journal of Clinical Endocrinology and Metabolism, 105(9), 3015–3024. https://doi.org/10.1210/clinem/dgaa419
17. Pal, R., Arya, A. K., Aggarwal, A., Singh, P., Dahiya, D., Sood, A., Singh, T., Ram, S., Bhansali, A., & Bhadada, S. K. (2020). Weight gain after curative parathyroidectomy predicts increase in bone mineral density in patients with symptomatic primary hyperparathyroidism. Clinical Endocrinology, 93(1), 28–35. https://doi.org/10.1111/cen.14195
18. Singh, P., Vadi, S. K., Saikia, U. N., Sood, A., Dahiya, D., Arya, A. K., Behera, A., Mukherjee, S., Arvindkumar, S. M., & Bhadada, S. K. (2019). Minimally invasive parathyroid carcinoma-A missing entity between parathyroid adenoma and carcinoma: Scintigraphic and histological features. Clinical Endocrinology, 91(6), 842–850. https://doi.org/10.1111/cen.14088
19. Singh, A., Mia, M. M., Cibi, D. M., Arya, A. K., Bhadada, S. K., & Singh, M. K. (2019). Deficiency in the secreted protein Semaphorin3d causes abnormal parathyroid development in mice. The Journal of Biological Chemistry, 294(21), 8336–8347. https://doi.org/10.1074/jbc.RA118.007063
20. Arya, A. K., Bhadada, S. K., Mukherjee, S., Singh, P., Rana, S. S., Dahiya, D., Sood, A., Saikia, U. N., Prakash, M., Bhasin, D. K., Behera, A., Walia, R., & Bhansali, A. (2018). Frequency & predictors of pancreatitis in symptomatic primary hyperparathyroidism. The Indian Journal of Medical Research, 148(6), 721–727. https://doi.org/10.4103/ijmr.IJMR_353_16
21. Mukherjee, S., Bhadada, S. K., Arya, A. K., Singh, P., Sood, A., Dahiya, D., Ram, S., Saikia, U. N., & Behera, A. (2018). PRIMARY HYPERPARATHYROIDISM IN THE YOUNG: COMPARISON WITH ADULT PRIMARY HYPERPARATHYROIDISM. Endocrine Practice, 24(12), 1051–1056. https://doi.org/10.4158/EP-2018-0268
22. Bhadada, S. K., Arya, A. K., Mukhopadhyay, S., Khadgawat, R., Sukumar, S., Lodha, S., Singh, D. N., Sathya, A., Singh, P., & Bhansali, A. (2018). Primary hyperparathyroidism: insights from the Indian PHPT registry. Journal of Bone and Mineral Metabolism, 36(2), 238–245. https://doi.org/10.1007/s00774-017-0833-8
23. Arya, A. K., Bhadada, S. K., Singh, P., Sachdeva, N., Saikia, U. N., Dahiya, D., Behera, A., Bhansali, A., & Rao, S. D. (2017). Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas. Scientific Reports, 7(1), 3123. https://doi.org/10.1038/s41598-017-03143-8
24. Gopalaswamy, V., Dhibar, D. P., Gupta, V., Arya, A. K., Khandelwal, N., Bhansali, A., Garg, S. K., Agarwal, N., Rao, S. D., & Bhadada, S. K. (2017). ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY. Endocrine Practice, 23(6), 657–661. https://doi.org/10.4158/EP161394.OR
25. Bhadada, S. K., Arya, A. K., Parthan, G., & Singh, P. (2015). The resolution of anemia after curative parathyroidectomy is sustained even after a decade. Indian Journal of Endocrinology and Metabolism, 19(5), 691–692. https://doi.org/10.4103/2230-8210.163215
26. Arya, A. K., & Sachdeva, N. (2014). Changes in plasma intact parathyroid hormone levels following 24-hour incubation at room temperature as determined by Roche electrochemiluminescence PTH immunoassay. Clinical Laboratory, 60(4), 689–692. https://doi.org/10.7754/clin.lab.2013.130419
27. Varshney, S., Bhadada, S. K., Arya, A. K., Sharma, S., Behera, A., Bhansali, A., & Rao, S. D. (2014). Changes in parathyroid proteome in patients with primary hyperparathyroidism due to sporadic parathyroid adenomas. Clinical Endocrinology, 81(4), 614–620. https://doi.org/10.1111/cen.12479
28. Varshney, S., Bhadada, S. K., Sachdeva, N., Arya, A. K., Saikia, U. N., Behera, A., & Rao, S. D. (2013). Methylation status of the CpG islands in vitamin D and calcium-sensing receptor gene promoters does not explain the reduced gene expressions in parathyroid adenomas. The Journal of Clinical Endocrinology and Metabolism, 98(10), E1631–E1635. https://doi.org/10.1210/jc.2013-1699
29. Varshney, S., Bhadada, S. K., Saikia, U. N., Sachdeva, N., Behera, A., Arya, A. K., Sharma, S., Bhansali, A., Mithal, A., & Rao, S. D. (2013). Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians. European Journal of Endocrinology, 169(1), 109–116. https://doi.org/10.1530/EJE-13-0085
30. Bhadada, S. K., Rastogi, A., Steenackers, E., Boudin, E., Arya, A., Dhiman, V., Bhansali, A., & Van Hul, W. (2013). Novel SOST gene mutation in a sclerosteosis patient and her parents. Bone, 52(2), 707–710. https://doi.org/10.1016/j.bone.2012.10.009